AOR

The Archives of Ophthalmological Research aims to publish issues related to publish articles of the highest scientific and clinical value at an international level, and accepts articles on these topics. The target audience of the journal included specialists and physicians working in ophthalmology, and other health professionals interested in these fields.

EndNote Style
Index
Case Report
Misdiagnosis and mismanagement in stage 4 best vitelliform macular dystrophy: a case report highlighting the role of multimodal imaging
Best vitelliform macular dystrophy (BVMD) is a typically autosomal dominant retinal disorder characterized by accumulationof lipofuscin in the macula, leading to progressive visual impairment. We report the case of a 42-year-old male diagnosedwith stage 4 BVMD (vitelloruptive stage) who was previously mismanaged with multiple intravitreal anti-VEGF injectionsunder the incorrect assumption of exudative pathology. Fundus photography revealed the characteristic “scrambled egg”appearance, while optical coherence tomography and fundus autofluorescence demonstrated hyperreflective subretinaldeposits and hyperautofluorescence without any evidence of fluid accumulation or choroidal neovascularization. Despite theabsence of electrooculography data, the diagnosis was supported by multimodal imaging. This case highlights the importanceof accurate diagnosis and staging of BVMD, and emphasizes the need to avoid unnecessary therapeutic interventions in thenon-exudative stages of the disease.


1. Maggon R, Parihar J, Vats DP, Mathur V. Best’s vitelliform macular dystrophy. Med J Armed Forces India. 2008;64(4):379-381. doi:10.1016/S0377-1237(08)80035-4
2. Boon CJ, Theelen T, Hoefsloot EH, et al. Clinical and molecular genetic analysis of best vitelliform macular dystrophy. Retina. 2009;29(6):835-847. doi:10.1097/IAE.0b013e31819d4fda
3. Bianco L, Arrigo A, Antropoli A, et al. Multimodal imaging in best vitelliform macular dystrophy: literature review and novel insights. Eur J Ophthalmol. 2024;34(1):39-51. doi:10.1177/11206721231166434
4. Lima de Carvalho JR Jr, Paavo M, Chen L, Chiang J, Tsang SH, Sparrow JR. Multimodal imaging in best vitelliform macular dystrophy. Invest Ophthalmol Vis Sci. 2019;60(6):2012-2022. doi:10.1167/iovs.19-26571
5. Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, Petrukhin K. Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2000;97(23):12758-12763. doi:10.1073/pnas.220402097
6. Brecher R, Bird AC. Adult vitelliform macular dystrophy. Eye (Lond). 1990;4(Pt 1):210-215. doi:10.1038/eye.1990.28
7. Weingeist TA, Kobrin JL, Watzke RC. Histopathology of best’s macular dystrophy. Arch Ophthalmol. 1982;100(7):1108-1114. doi:10.1001/archopht.1982.01030040086016
8. Gass JDM. Stereoscopic atlas of macular diseases. 4th ed. Mosby; 1997.
9. Deutman AF, Hoyng CB. Macular dystrophies. In: Schachat AP, Hengst TC, eds. Medical Retina. 3rd ed. Mosby; 2001:1226.
10. Khan KN, Mahroo OA, Islam F, Webster AR, Moore AT, Michaelides M. Outcomes of CNV complicating BEST1-related retinopathy. Retina. 2017;37(7):1360-1370. doi:10.1097/IAE.0000000000001357
11. Creel DJ. The electrooculogram. Handb Clin Neurol. 2019;160:495-499. doi:10.1016/B978-0-444-64032-1.00033-3
Volume 2, Issue 3, 2025
Page : 55-57
_Footer